Day Low: | 0.015
| Day High: | 0.016
|
52 Week Low: | 0.015
|
52 Week High: | 0.047
|
Market Cap ($ M): | $13,404,165.00
|
Cash ($ M): | $3.05M
|
Volume: | 1,223,776
|
Ticker Symbol: | ASX:CHM |
Website: | |
Yahoo Finance: | |
Address: | 62 Lygon Street, Carlton, Australia |
Phone Number: | 61 3 9824 5254 |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
If you would like to receive our free newsletter via email, simply enter your email address below & click subscribe.
Tweet with hash tag #miningfeeds or @miningfeeds and your tweets will be displayed across this site.
North Arrow Minerals Inc. | NAR.V | +1,150.00% |
MTB.V | +50.00% | |
DMG.AX | +50.00% | |
Rare Element Resources Ltd. | REE | +44.19% |
BSE.AX | +34.21% | |
CASA.V | +30.00% | |
VO.V | +30.00% | |
AME.V | +25.00% | |
DOS.V | +25.00% | |
AUK.AX | +20.00% |
September 13, 2024
© 2024 MiningFeeds.com. All rights reserved.
(This site is formed from a merger of Mining Nerds and Highgrade Review.)